At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 331 enrolled
Drug / intervention
secukinumab 150 mgdrug
Likely dose
secukinumab 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Multicenter Study Assessing Short and Long-term Efficacy, Safety, and Tolerability of Sub-cutaneous Secukinumab in Subjects of Body Weight 90 kg or Higher With Moderate to Severe Chronic Plaque-type Psoriasis
In Brief
A Phase 3 clinical trial evaluating secukinumab 150 mg for Moderate to Severe Chronic Plaque-type Psoriasis. Completed, enrolled 331 participants across 67 sites in 7 countries.
Detailed Summary
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Czechia, Germany, Hungary, Italy, Russia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartJun 2018
Primary CompletionSep 2019
Study CompletionJul 2020
TodayJul 2026
First PostedApr 20, 2018
Enrollment StartJun 25, 2018
Primary CompletionSep 13, 2019
Study CompletionJul 15, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.2 years ago
Interventions
secukinumab 150 mgdrug
sub-cutaneous secukinumab prefilled syringe 150 mg